Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study

Journal of Neurology, Neurosurgery and Psychiatry 2022 March 09;jnnp-2021-327480 Michel Dominique Ferrari, Uwe Reuter, Peter J Goadsby , Gabriel Paiva da Silva Lima, Subhayan Monda, Shihua Wen, Nadia Tenenbaum, Shaloo Pandhi, Michel Lanteri-Minet, Tracy Stites Abstract Objective: To evaluate individual